Literature DB >> 26046083

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

André J Scheen1.   

Abstract

The recent data reported by Tang and colleagues in Science Translational Medicine suggest that alpha-2 adrenoceptors (α2AAR) genetic heterogeneity may explain diverging results regarding the effects of α2AAR antagonists on insulin secretion and glucose control in patients with type 2 diabetes. They first confirmed that the risk variant for rs553668 (the A allele for a single-nucleotide polymorphism in ADRA2A) is likely to cause defective insulin secretion in human pancreatic islets. Second they showed that blocking α2AAR with yohimbine dose-dependently improves the reduced insulin secretion during an oral glucose tolerance test in patients with the risk variant. The successful translation of genomic information into clinical intervention in patients with type 2 diabetes provides proof of concept for the feasibility of individualized treatment based on genotype.

Entities:  

Keywords:  Alpha-2 adrenoceptor (α2AAR); genotype; insulin secretion; personalized medicine; type 2 diabetes

Year:  2015        PMID： 26046083      PMCID： PMC4437928          DOI： 10.3978/j.issn.2305-5839.2015.03.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  20 in total

1.  Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes.

Authors:  C G Ostenson; J Pigon; J C Doxey; S Efendic
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958

2.  Personalising metformin therapy: a clinician's perspective.

Authors:  André J Scheen
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-19       Impact factor: 32.069

3.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

Review 4.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Authors:  Steven E Kahn; Mark E Cooper; Stefano Del Prato
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

5.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

6.  Genetic association of adrenergic receptor alpha 2A with obesity and type 2 diabetes.

Authors:  Ewa-Carin Långberg; Mohammed Seed Ahmed; Suad Efendic; Harvest F Gu; Claes-Göran Östenson
Journal:  Obesity (Silver Spring)       Date:  2013-06-11       Impact factor: 5.002

7.  Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus.

Authors:  V L Broadstone; M A Pfeifer; V Bajaj; J I Stagner; E Samols
Journal:  Diabetes       Date:  1987-08       Impact factor: 9.461

8.  The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.

Authors:  Leen M 't Hart; Andreas Fritsche; Giel Nijpels; Nienke van Leeuwen; Louise A Donnelly; Jacqueline M Dekker; Marjan Alssema; Joao Fadista; Françoise Carlotti; Anette P Gjesing; Colin N A Palmer; Timon W van Haeften; Silke A Herzberg-Schäfer; Annemarie M C Simonis-Bik; Jeanine J Houwing-Duistermaat; Quinta Helmer; Joris Deelen; Bruno Guigas; Torben Hansen; Fausto Machicao; Gonneke Willemsen; Robert J Heine; Mark H H Kramer; Jens J Holst; Eelco J P de Koning; Hans-Ulrich Häring; Oluf Pedersen; Leif Groop; Eco J C de Geus; P Eline Slagboom; Dorret I Boomsma; Elisabeth M W Eekhoff; Ewan R Pearson; Michaela Diamant
Journal:  Diabetes       Date:  2013-05-14       Impact factor: 9.461

9.  Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

Authors:  S A Schäfer; O Tschritter; F Machicao; C Thamer; N Stefan; B Gallwitz; J J Holst; J M Dekker; L M 't Hart; L M t'Hart; G Nijpels; T W van Haeften; H U Häring; A Fritsche
Journal:  Diabetologia       Date:  2007-07-28       Impact factor: 10.122

Review 10.  β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.

Authors:  Philippe A Halban; Kenneth S Polonsky; Donald W Bowden; Meredith A Hawkins; Charlotte Ling; Kieren J Mather; Alvin C Powers; Christopher J Rhodes; Lori Sussel; Gordon C Weir
Journal:  Diabetes Care       Date:  2014-05-08       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.